ADMA Biologics Ownership
| ADMA Stock | USD 16.73 0.86 4.89% |
ADMA Stock Ownership Analysis
About 88.0% of the company shares are held by institutions such as insurance companies. The company had not issued any dividends in recent years. ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey. Adma Biologics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 527 people. For more info on ADMA Biologics please contact Adam Grossman at 201 478 5552 or go to https://www.admabiologics.com.ADMA Biologics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific ADMA Biologics insiders, such as employees or executives, is commonly permitted as long as it does not rely on ADMA Biologics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases ADMA Biologics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
ADMA Biologics Outstanding Bonds
ADMA Biologics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. ADMA Biologics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most ADMA bonds can be classified according to their maturity, which is the date when ADMA Biologics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| ABNANV 3324 13 MAR 37 Corp BondUS00084DAV29 | View | |
| ABNANV 1542 16 JUN 27 Corp BondUS00084DAU46 | View | |
| ABNANV 247 13 DEC 29 Corp BondUS00084DAW02 | View | |
| ABNANV 48 18 APR 26 Corp BondUS00084DAL47 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| ABNANV 475 28 JUL 25 Corp BondUS00080QAF28 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether ADMA Biologics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ADMA Biologics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Adma Biologics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Adma Biologics Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ADMA Biologics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade ADMA Stock refer to our How to Trade ADMA Stock guide.You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ADMA Biologics. If investors know ADMA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ADMA Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of ADMA Biologics is measured differently than its book value, which is the value of ADMA that is recorded on the company's balance sheet. Investors also form their own opinion of ADMA Biologics' value that differs from its market value or its book value, called intrinsic value, which is ADMA Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ADMA Biologics' market value can be influenced by many factors that don't directly affect ADMA Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ADMA Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if ADMA Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ADMA Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.